Company News 

Indivior: too risky to hold

Indivior: too risky to hold

Can Indivior (INDV) recover from a major setback in its ongoing patent dispute? A US court concluded that an unbranded version of the group’s opioid addiction treatment – made by Indian pharma company Dr Reddy’s – does not breach Individor's patent, clearing the way for lower-priced competition. The highs of recent months – when many courts ruled in favour of Indivior’s various legal proceedings – have been replaced with a crashing comedown. Individor intends to appeal the US District Court for the District of Delaware's decision. The shares plummeted 31 per cent on the day of the announcement and have only made up a small amount of ground since. 

To continue reading, subscribe today

and enjoy unlimited access to the following:

  • Tips of the Week
  • Funds coverage
  • Weekly features on big investment themes
  • Trading ideas
  • Comprehensive companies coverage
  • Economic analysis
Subscribe
Subscribe to Investors Chronicle

Subscribe today

Full access for just £3.37 a week:

• Tips and recommendations - to beat the market 
• Portfolio clinic & Mr Bearbull - build a well-planned portfolio 
• Expert tools - track and manage investments effortlessly
• Plus free delivery to your home or office

Subscribe Now